

Cancer Vaccine Market - A Global and Regional Analysis: Focus on Vaccine Type, Technology Type, and Region - Analysis and Forecast, 2025-2035

<https://marketpublishers.com/r/C25A549D7825EN.html>

Date: June 2026

Pages: 0

Price: US\$ 4,900.00 (Single User License)

ID: C25A549D7825EN

Abstracts

Hard copy option is available on any of the options above at an additional charge of \$500. Please email us at order@marketpublishers.com with your request.

This report will be delivered in 7-10 working days.

Global Cancer Vaccine Market, Analysis and Forecast: 2025-2035

The global cancer vaccine market is witnessing significant growth due to rising cancer prevalence, increasing adoption of immunotherapies, and advancements in vaccine development technologies. Cancer vaccines, both preventive and therapeutic, aim to stimulate the immune system to prevent or combat cancer. While preventive vaccines such as HPV and HBV vaccines have achieved broad adoption, therapeutic cancer vaccines are gaining traction with the development of personalized and targeted therapies.

Growth in the cancer vaccine market is supported by the growing investments in R&D, particularly in mRNA vaccine platforms and neoantigen-based vaccines, are fuelling innovation across the cancer vaccine market. Companies are leveraging AI and genome sequencing to design individualized vaccines targeting tumor-specific mutations. The FDA approvals of vaccines such as Sipuleucel-T and BCG for prostate and bladder cancer, respectively, have further validated the clinical potential of cancer vaccines.

The increasing incidence of cancer globally, alongside unmet medical needs in oncology, is driving demand for novel vaccine approaches that can provide long-term

immune memory and minimal side effects. Immunotherapy's success in other areas has also increased confidence in vaccine-based cancer treatments, spurring regulatory support and clinical trials across solid and hematologic malignancies.

Regional market growth is underpinned by strong healthcare infrastructure in North America and Europe, rising awareness, and supportive reimbursement policies. The Asia-Pacific region is emerging as a high-growth area due to expanding healthcare access, government initiatives, and local manufacturing capabilities.

Despite positive growth prospects, the cancer vaccine market faces challenges such as high R&D costs, complex regulatory pathways, and limited efficacy of some therapeutic vaccines. Additionally, patient-specific manufacturing and storage logistics for personalized vaccines pose scalability concerns.

The competitive landscape includes major players such as Merck, Dynavax Technologies and Dendreon, as well as innovative biotech firms like Moderna, BioNTech, Transgene, Imugene, and OSE Immunotherapeutics. Collaborations between pharma and biotech companies, academic institutions, and research consortia are accelerating pipeline development.

Looking ahead, the cancer vaccine market is projected to grow steadily, driven by the expansion of personalized medicine, next-generation vaccine platforms, and increased funding for oncology research. Integration of digital health for patient tracking and AI-assisted trial designs is expected to optimize treatment outcomes and regulatory timelines.

Market Segmentation:

Segmentation 1: by Vaccine Type

Preventive Vaccines

Gardasil

HEPLISAV-B

Therapeutic Vaccines

Bacillus Calmette-Guérin (BCG)

Sipuleucel-T (Provenge)

Segmentation 2: by Technology Type

Recombinant

Cell-based

Others

Segmentation 3: by Region

North America

Europe

Asia-Pacific

The cancer vaccine market will continue to evolve with a strong focus on therapeutic innovations, including neoantigen-targeted and mRNA-based approaches. Advancements in precision oncology and global commitment to reducing cancer burden will shape the trajectory of the cancer vaccine market as a cornerstone of future cancer care.

Contents

Executive Summary
Scope and Definition
Market/Product Definition
Inclusion and Exclusion
Key Questions Answered
Analysis and Forecast Note

1. GLOBAL CANCER VACCINE MARKET: INDUSTRY ANALYSIS

1.1 Market Overview and Ecosystem
1.2 Epidemiological Analysis
1.3 Key Market Trends
 1.3.1 Impact Analysis
1.4 Patent Analysis
 1.4.1 Patent Filing Trend (by Country)
 1.4.2 Patent Filing Trend (by Year)
1.5 Regulatory Landscape
1.6 Ongoing Clinical Trials
1.7 Market Dynamics
 1.7.1 Overview
 1.7.2 Market Drivers
 1.7.3 Market Restraints
 1.7.4 Market Opportunities

2. GLOBAL CANCER VACCINE MARKET, BY VACCINE TYPE, \$MILLION, 2023-2035

2.1 Preventive Vaccines
 2.1.1 Gardasil
 2.1.2 HEPLISAV-B
2.2 Therapeutic Vaccines
 2.2.1 Bacillus Calmette-Guérin (BCG)
 2.2.2 Sipuleucel-T (Provenge)

3. GLOBAL CANCER VACCINE MARKET, BY TECHNOLOGY TYPE, \$MILLION, 2023-2035

- 3.1 Recombinant
- 3.2 Cell-based
- 3.3 Others

4. GLOBAL CANCER VACCINE MARKET, BY REGION, \$MILLION, 2023-2035

- 4.1 North America
 - 4.1.1 Market Dynamics
 - 4.1.2 Market Sizing and Forecast
 - 4.1.3 North America Cancer Vaccine Market, by Country
 - 4.1.3.1 U.S.
- 4.2 Europe
 - 4.2.1 Market Dynamics
 - 4.2.2 Market Sizing and Forecast
 - 4.2.3 Europe Cancer Vaccine Market, by Country
 - 4.2.3.1 U.K.
 - 4.2.3.2 France
 - 4.2.3.3 Germany
 - 4.2.3.4 Italy
 - 4.2.3.5 Spain
- 4.3 Asia-Pacific
 - 4.3.1 Market Dynamics
 - 4.3.2 Market Sizing and Forecast
 - 4.3.3 Asia-Pacific Cancer Vaccine Market, by Country
 - 4.3.3.1 Japan

5. GLOBAL CANCER VACCINE MARKET, COMPETITIVE LANDSCAPE AND COMPANY PROFILES

- 5.1 Competitive Landscape
 - 5.1.1 Mergers and Acquisitions
 - 5.1.2 Partnership, Alliances and Business Expansion
 - 5.1.3 New Offerings
 - 5.1.4 Regulatory Activities
 - 5.1.5 Funding Activities
- 5.2 Company Profiles
 - 5.2.1 Merck & Co., Inc.,
 - 5.2.1.1 Overview
 - 5.2.1.2 Top Products / Product Portfolio

- 5.2.1.3 Top Competitors
- 5.2.1.4 Target Customers/End-Users
- 5.2.1.5 Key Personnel
- 5.2.1.6 Analyst View
- 5.2.2 Dynavax Technologies Corporation
 - 5.2.2.1 Overview
 - 5.2.2.2 Top Products / Product Portfolio
 - 5.2.2.3 Top Competitors
 - 5.2.2.4 Target Customers/End-Users
 - 5.2.2.5 Key Personnel
 - 5.2.2.6 Analyst View
- 5.2.3 Dendreon Pharmaceuticals LLC
 - 5.2.3.1 Overview
 - 5.2.3.2 Top Products / Product Portfolio
 - 5.2.3.3 Top Competitors
 - 5.2.3.4 Target Customers/End-Users
 - 5.2.3.5 Key Personnel
 - 5.2.3.6 Analyst View
- 5.2.4 Moderna, Inc
 - 5.2.4.1 Overview
 - 5.2.4.2 Top Products / Product Portfolio
 - 5.2.4.3 Top Competitors
 - 5.2.4.4 Target Customers/End-Users
 - 5.2.4.5 Key Personnel
 - 5.2.4.6 Analyst View
- 5.2.5 BioNTech SE
 - 5.2.5.1 Overview
 - 5.2.5.2 Top Products / Product Portfolio
 - 5.2.5.3 Top Competitors
 - 5.2.5.4 Target Customers/End-Users
 - 5.2.5.5 Key Personnel
 - 5.2.5.6 Analyst View
- 5.2.6 Transgene S.A.
 - 5.2.6.1 Overview
 - 5.2.6.2 Top Products / Product Portfolio
 - 5.2.6.3 Top Competitors
 - 5.2.6.4 Target Customers/End-Users
 - 5.2.6.5 Key Personnel
 - 5.2.6.6 Analyst View

5.2.7 Imugene Limited

5.2.7.1 Overview

5.2.7.2 Top Products / Product Portfolio

5.2.7.3 Top Competitors

5.2.7.4 Target Customers/End-Users

5.2.7.5 Key Personnel

5.2.7.6 Analyst View

5.2.8 Ose-Immuno

5.2.8.1 Overview

5.2.8.2 Top Products / Product Portfolio

5.2.8.3 Top Competitors

5.2.8.4 Target Customers/End-Users

5.2.8.5 Key Personnel

5.2.8.6 Analyst View

5.2.9 Barinthus Biotherapeutics

5.2.9.1 Overview

5.2.9.2 Top Products / Product Portfolio

5.2.9.3 Top Competitors

5.2.9.4 Target Customers/End-Users

5.2.9.5 Key Personnel

5.2.9.6 Analyst View

5.2.10 Others

6. RESEARCH METHODOLOGY

List Of Figures

LIST OF FIGURES

Figure: Global Cancer Vaccine Market Coverage

Figure: Global Cancer Vaccine Market Key Trends, Impact Analysis, 2023-2035

Figure: Global Cancer Vaccine Market, Patent Analysis, January 2022-March 2025

List Of Tables

LIST OF TABLES

Table: Global Cancer Vaccine Market (by Vaccine Type), \$Million, 2023-2035

Table: Global Cancer Vaccine Market (by Technology Type), \$Million, 2023-2035

Table: Global Cancer Vaccine Market (by Region), \$Million, 2023-2035

I would like to order

Product name: Cancer Vaccine Market - A Global and Regional Analysis: Focus on Vaccine Type, Technology Type, and Region - Analysis and Forecast, 2025-2035

Product link: <https://marketpublishers.com/r/C25A549D7825EN.html>

Price: US\$ 4,900.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/C25A549D7825EN.html>